Clinical Trial Update: HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update for Holmium-166 radioembolization (HEPAR Primary) in patients with hepatocellular carcinoma, including non-resectable disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Holmium-166 radioembolization (holmium-166 radioembolization)

Snippet

Sponsor: UMC Utrecht | Conditions: Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: COMPLETED